The composite of cardiovascular death or HF hospitalizations/urgent visits are consistently reduced by SGLT2 inhibitors across multiple subgroups, including women, older patients, Black individuals, and those with impaired renal function. The gene discussed is SLC5A2; the disease is hydrops fetalis.